Printer Friendly

AnGes MG Patents HVJ Envelope Vector in US.

Tokyo, Japan, Aug 17, 2005 - (JCNN) - AnGes MG announced on August 15 that a basic patent on its proprietary HVJ envelope vector technology was approved in the US and the US Patent and Trademark Office has made announcement in a Patent Gazette (US 6913923B2).

The newly approved patent covers the vector itself, applications and the processing method. The HVJ envelope vector is involved in gene induction.

AnGes MG is also applying for a patent on the HVJ envelop vector in Japan, Europe, Canada, Australia, China, Korea and Taiwan.

Further, in collaboration with Ishihara Sangyo Kaisha, the company is distributing GenomeONE, a gene transfection kit that uses the HVJ envelop vector, in Japan.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Aug 18, 2005
Words:128
Previous Article:Sysmex, Bio-Rad Laboratories to Jointly Offer Hematology Solution in US.
Next Article:Nisshin Seifun, French Boulangerie Maison Kayser to Jointly Introduce Bread Flour for Commercial Use.


Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Nikko Principal, AnGes MG Establish Fund for Pharmaceutical, Medical and Biotechnology Companies.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
AnGes MG to Market and Distribute BioMarin's Naglazyme in Japan.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters